102 related articles for article (PubMed ID: 21468918)
1. Biodistribution and improved anticancer effect of NIK-siRNA in combination with 5-FU for hepatocellular carcinoma.
Kang SS; Cho HA; Kim JS
Arch Pharm Res; 2011 Jan; 34(1):79-86. PubMed ID: 21468918
[TBL] [Abstract][Full Text] [Related]
2. Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-kappaB-inducing kinase-specific siRNA using liver-targeting liposomes.
Cho HA; Park IS; Kim TW; Oh YK; Yang KS; Kim JS
Arch Pharm Res; 2009 Jul; 32(7):1077-86. PubMed ID: 19641890
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice.
Sagawa T; Yamada Y; Takahashi M; Sato Y; Kobune M; Takimoto R; Fukaura J; Iyama S; Sato T; Miyanishi K; Matsunaga T; Takayama T; Kato J; Sasaki K; Hamada H; Niitsu Y
Hepatology; 2008 Sep; 48(3):828-40. PubMed ID: 18756484
[TBL] [Abstract][Full Text] [Related]
4. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
5. EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma.
Gao J; Yu Y; Zhang Y; Song J; Chen H; Li W; Qian W; Deng L; Kou G; Chen J; Guo Y
Biomaterials; 2012 Jan; 33(1):270-82. PubMed ID: 21963149
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo.
Kojiro S; Yano H; Ogasawara S; Momosaki S; Takemoto Y; Nishida N; Kojiro M
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):129-37. PubMed ID: 16706824
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect of alpha-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice.
Ma SH; Chen GG; Yip J; Lai PB
Gene Ther; 2010 Jul; 17(7):905-12. PubMed ID: 20336154
[TBL] [Abstract][Full Text] [Related]
8. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of nuclear factor-κB activity by small interfering RNA in esophageal squamous cell carcinoma cell lines.
Hatata T; Higaki K; Nanba E; Tatebe S; Ikeguchi M
Oncol Rep; 2011 Sep; 26(3):659-64. PubMed ID: 21617867
[TBL] [Abstract][Full Text] [Related]
10. [Experimental research of therapeutic effect on hepatocellular carcinoma of targeting SMYD3 gene inhibition by RNA interference].
Xu JY; Chen LB; Xu JY; Yang Z; Xu RH; Wei HY
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):481-4. PubMed ID: 16772086
[TBL] [Abstract][Full Text] [Related]
11. TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU.
Zhao J; Zhang X; Shi M; Xu H; Jin J; Ni H; Yang S; Dai J; Wu M; Guo Y
Hepatology; 2006 Jul; 44(1):205-15. PubMed ID: 16799960
[TBL] [Abstract][Full Text] [Related]
12. Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes.
Sonoke S; Ueda T; Fujiwara K; Sato Y; Takagaki K; Hirabayashi K; Ohgi T; Yano J
Cancer Res; 2008 Nov; 68(21):8843-51. PubMed ID: 18974128
[TBL] [Abstract][Full Text] [Related]
13. [Experimental research of targeting hTERT gene inhibited in hepatocellular carcinoma therapy by RNA interference].
Zhang PH; Tu ZG; Yang MQ; Huang WF; Zou L; Zhou YL
Ai Zheng; 2004 Jun; 23(6):619-25. PubMed ID: 15191658
[TBL] [Abstract][Full Text] [Related]
14. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes.
Yin T; Wang P; Li J; Wang Y; Zheng B; Zheng R; Cheng D; Shuai X
Biomaterials; 2014 Jul; 35(22):5932-43. PubMed ID: 24746965
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer.
Yano J; Hirabayashi K; Nakagawa S; Yamaguchi T; Nogawa M; Kashimori I; Naito H; Kitagawa H; Ishiyama K; Ohgi T; Irimura T
Clin Cancer Res; 2004 Nov; 10(22):7721-6. PubMed ID: 15570006
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma.
Wang H; Jiang H; Zhou M; Xu Z; Liu S; Shi B; Yao X; Yao M; Gu J; Li Z
Cancer Lett; 2009 Jun; 279(1):30-8. PubMed ID: 19217205
[TBL] [Abstract][Full Text] [Related]
17. N-Myc down-regulated gene 1 mediates proliferation, invasion, and apoptosis of hepatocellular carcinoma cells.
Yan X; Chua MS; Sun H; So S
Cancer Lett; 2008 Apr; 262(1):133-42. PubMed ID: 18207320
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
[TBL] [Abstract][Full Text] [Related]
19. Transfection of Smac sensitizes tumor cells to etoposide-induced apoptosis and eradicates established human hepatoma in vivo.
Zhao J; Jin J; Zhang X; Shi M; Dai J; Wu M; Wang R; Guo Y
Cancer Gene Ther; 2006 Apr; 13(4):420-7. PubMed ID: 16211087
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA.
Gao J; Chen H; Yu Y; Song J; Song H; Su X; Li W; Tong X; Qian W; Wang H; Dai J; Guo Y
Biomaterials; 2013 Dec; 34(38):10084-98. PubMed ID: 24060417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
